Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters

Cooper City, Florida Clinical Trials

A listing of Cooper City, Florida clinical trials actively recruiting patient volunteers.

RESULTS

Found (22) clinical trials

A Multicenter, Open-Label Evaluation of Treatment Satisfaction, Tolerability, Safety, and Preference of Sumavel DosePro for Treatment of Migraine in Subjects Currently Treated with Triptans Patient Inclusion Criteria: Men or Women 18 to 65 years of age Have a history of 2 to 6 migraine headaches (on average) per month Suffering ...

Phase

2.38 miles

Learn More »

A Study to Evaluate the Effect of Testosterone Replacement Therapy (TRT) on the Incidence of Major Adverse Cardiovascular Events (MACE) and Efficacy Measures in Hypogonadal Men ( TRAVERSE )

This is a blinded and placebo-controlled study of topical testosterone replacement therapy (TRT) in symptomatic hypogonadal men with increased risk for cardiovascular (CV) disease.

Phase

2.38 miles

Learn More »

A Study of Abemaciclib (LY2835219) in Combination With Fulvestrant Compared to Chemotherapy in Women With HR Positive HER2 Negative Metastatic Breast Cancer

The reason for this study is to compare the efficacy of abemaciclib, in combination with fulvestrant, to that of physician's choice of chemotherapy in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer that has spread to internal organs. Your participation in this trial ...

Phase

2.38 miles

Learn More »

Clinical Impact of Acthar in the Psoriatic Arthritis Patient (CLIPS)

The study is an investigator initiated study (IIS) single arm treatment, single center where patients will receive active treatment with ActharTM 80 units twice weekly for 4 weeks followed by 40 units twice weekly until week 12. 2-End points: 1.Primary Clinical Endpoint To demonstrate the efficacy of Acthar for the ...

Phase

4.73 miles

Learn More »

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous thromboembolic events (VTEs) when given to participants with rheumatoid arthritis.

Phase

4.73 miles

Learn More »

Study Estimating the Clinical Difference Between 300 mg and 150 mg of Secukinumab Following Dose Escalation to 300 mg in Patients With Ankylosing Spondylitis

Study estimating the clinical difference between 300 mg and 150 mg of secukinumab following dose escalation to 300 mg in patients with ankylosing spondylitis

Phase

4.73 miles

Learn More »

Efficacy Safety and Tolerability Study of Apremilast to Treat Early Oligoarticular Psoriatic Arthritis.

This clinical study will test the effects of a drug called apremilast in oligoarticular psoriatic arthritis with less than 2 years of disease duration. In previous studies, apremilast has been shown to be safe and efficacious in reducing signs and symptoms of psoriatic arthritis, as well as improving physical function. ...

Phase

4.73 miles

Learn More »

A Study to Evaluate the Impact of Apremilast (CC-10004) on MRI Outcomes in Subjects With Psoriatic Arthritis

Approximately 120 subjects will receive apremilast 30 mg BID, after a 5-day titration period, with or without MTX. All subjects will be permitted to take NSAIDs and/or low-dose oral glucocorticoids (prednisone 10 mg/day or equivalent) throughout the study. The NSAIDs and low-dose oral glucocorticoids must be on a stable regimen ...

Phase

4.73 miles

Learn More »

Apixaban for the Acute Treatment of Venous Thromboembolism in Children

To assess the safety and descriptive efficacy of apixaban in pediatric subjects requiring anticoagulation for the treatment of a VTE.

Phase

5.69 miles

Learn More »

Standardized Treatment of Pulmonary Exacerbations II

The study will assess the non-inferiority of 10 days versus 14 days treatment duration among patients who have an early robust improvement (ERR subjects) and the superiority of 21 days versus 14 days treatment duration among the subjects who do not meet the definition of ERR (non-ERR; NERR). Subjects will ...

Phase

5.69 miles

Learn More »